COVID Coronavirus vaccine news: Large pharma companies, which are doing the last trial of their Kovid-19 vaccine, have signed agreements for vaccines from many countries. Two high power committees have been formed in India for vaccine-related issues. As the trial of the different vaccines of the coronavirus progresses, new deals are coming out. Most of the rich countries have signed crores of dosages with some vaccine developers. The Government of India has created two high power committees that are discussing issues related to vaccine development. The committee headed by Prime Minister's Principal Scientific Advisor Dr. K Vijayaraghavan has to oversee Indian vaccine development. In addition, they have to monitor the progress of foreign vaccines given to Indian manufacturers. The government is also taking many companies with 'fill and finish'. According to The Indian Express, these companies will not make vaccines. But just fill the vaccine in the vials and finish the production. This requires large assembly lines.
Second committee for what happens after vaccine formation
The second government committee is headed by Dr. VK Paul, a member of the NITI Aayog. The task of this committee is to bring vaccines to the people. The committee includes secretaries of the Ministry of Health, Finance, Commerce and External Affairs, besides several top scientists. That is, when the vaccine will be ready, it is the responsibility of this committee to prepare its stock and cold-chain. This committee is monitoring the storage needs of vaccine candidates undergoing advanced stage trials. Moderna's vaccine has to be stored at a temperature of at least -70 degrees Celsius, whereas this is not the case with Bharat Biotech or Oxford's Vaccine. This committee also has to decide whether the vaccine will be applied at any centers or outside.
COVAX will have vaccine availability fixed
According to the report, the government is not in direct contact with any foreign vaccine manufacturer. But it has a stake in the vaccine supply through GAVI and Coalition Epidemic Preparedness Innovations (CEPI). India is also working on a third way. That is COVAX which is an alliance of WHO, GAVI, and CEPI. All three have come together so that the demand for vaccines can be met in all countries. The objective of COVAX is that at least 20% of the requirement of all countries (except developed countries) can be supplied through it.
Trial of 16 people in the first phase in AIIMS
The first phase trial of ICMR and Bharat Biotech's Kovid-19 indigenous vaccine has been stopped at AIIMS. Only 16 volunteers were vaccinated at AIIMS. With this, the goal of the trial of the first phase was achieved. A total of 100 people were to be vaccinated at AIIMS. Sources said that the pace of AIIMS was so slow in this trial that the target of the trial in the rest of the state institute and medical college was met. The first phase trial in AIIMS has now stopped.
How much will the vaccine cost?
The serum institute of India has fixed the price of the vaccine at around Rs 225. Whereas American company Moderna has said that the price of its vaccine can be between 50 to 60 dollars (Rs 3,700 to Rs 4,500). According to reports, Pfizer intends to sell the vaccine for around $ 45. However, this price will not be the same in every country. AstraZeneca, Johnson & Johnson, and Pfizer have indicated that they do not want to profit from the vaccine.
Russia: Vaccine to be given to people from next week
Russia has said that it will register its first vaccine against Corona on August 12. This vaccine from the Ministry of Defense and the Gamalaya Research Institute is going through a final visit to the trial. Russia's Health Minister Oleg Gridnev has said that vaccination will be given to medical professionals and the elderly first. The trial of this vaccine will also go on simultaneously.
Indian company made a big deal, commentary for Rs 225
The Serum Institute of India (SII) has signed a major deal with The Vaccine Alliance (GAVI) and The Bill & Milinda Gates Foundation to manufacture the Corona vaccine. Arrangements are made to make the crore doses available immediately. The Gates Foundation will fund $ 150 million (about Rs 1,125 crore) of risk funding to GAVI. This means that if the vaccine is unsuccessful in the last stage, then the cost of the vaccine made by then will be borne by GAVI. SII is currently manufacturing vaccine candidates from Oxford University, AstraZeneca, and Novavax. The company's vaccine will be made available in low and middle-income category countries (LMICs) for just $ 3 (about Rs. 225).
.png)
0 Comments